Sahajanand Medical Technologies IPO
Mainboard IPO · Open now · price band ₹327–₹344
Key points
- 100% offer for sale: the company gets no money. Existing shareholders are selling ₹475 cr of shares.
- GMP ₹15–21 (+4.4% to +6.1%) over ₹344. Unofficial, changes often.
- FY26: income ₹1,219 cr (+17.6%), profit ₹69.08 cr (+175%).
Subscription so far: 0.82x
Times the shares on offer that investors have applied for, by category (exchange data, updates a few times a day).
Timetable
- OpensThu 15 Oct
- ClosesMon 19 Oct
- AllotmentWed 21 Oct
- RefundThu 22 Oct
- Shares in dematThu 22 Oct
- ListingFri 23 Oct
Dates after the closing day are tentative and can shift by a day.
Why is Sahajanand Medical Technologies raising money?
This IPO is entirely an offer for sale. The company does not receive any money; the ₹475 cr goes to the shareholders who are selling. The business itself gets no new capital from this IPO.
Who is selling
- Samara Capital Markets Holding Ltd.Corporate₹223 cr
- Shree Hari TrustPromoter₹92.88 cr
- Dhirajkumar Savjibhai VasoyaPromoter₹68.8 cr
- NHPEA Sparkle Holding BVCorporate₹45.93 cr
- Kotak Pre-IPO Opportunities FundCorporate₹44.99 cr
Grey market premium (GMP)
Unofficial. GMP is what traders in an unregulated market say they will pay before listing. No exchange publishes it, it can change several times a day and it is often wrong on listing day. Range from 2 market websites, checked 18 Oct 2026, 03:23 PM IST.
About Sahajanand Medical Technologies
Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.
The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets.
The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024.
Financials (₹ crore)
Sahajanand Medical Technologies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 175% between the years ending March 31, 2026 and March 31, 2025.
| ₹ crore | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|---|
| Total Income | 354 | 1,219 | 1,036 | 909 |
| Profit After Tax | 15 | 69 | 25 | -7 |
| EBITDA | 49 | 171 | 128 | 110 |
| Net worth | 632 | 616 | 545 | 526 |
| Borrowing | 321 | 270 | 225 | 175 |
| Assets | 1,309 | 1,276 | 1,095 | 971 |
Restated figures from the offer document. A part-year period (for example 3 months to June) is not comparable with a full year.
Valuation and returns
| Jun 2026 | Mar 2026 | |
|---|---|---|
| ROE | 2.07% | 10.35% |
| ROCE | 3.16% | 11.57% |
| Debt/Equity | 0.33 | 0.27 |
| RoNW | 2.31% | 10.60% |
| PAT Margin | 4.29% | 5.71% |
| EBITDA Margin | 13.81% | 14.10% |
| NAV | 64.35 | 62.76 |
| P/B (x) | – | 5.48 |
P/E = price ÷ earnings per share. A negative P/E means the company made a loss. Compare with listed peers in the same business before reading much into it.
Promoters: Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust.
Issue details
- Price band
- ₹327–₹344
- Lot size
- 43 shares
- Minimum investment
- ₹14,792 (1 lot at ₹344)
- Total issue size
- ₹475 cr (1.38 crore shares)
- Fresh issue / OFS
- OFS only
- Face value
- ₹1 per share
- Reserved for
- QIB 50% · NII 15% · Retail 35%
- Anchor investors
- ₹140 cr (already allotted)
- Employee discount
- –
- Retail limit
- up to ₹2,00,000
- UPI mandate deadline
- 19-Oct-2026 (up to 5:00 PM)
- Listing on
- BSE, NSE
- Lead managers
- Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited , Nuvama Wealth Management Limited
- Registrar (allotment status)
- MUFG Intime India Private Limited · sahajanandmedical.ipo@in.mpms.mufg.com
Offer document (RHP) on NSE: download. It is long; the "Objects of the Offer" and "Risk Factors" chapters matter most.
Quick answers
Does Sahajanand Medical Technologies get the IPO money?
No. The IPO is 100% offer for sale, so all ₹475 cr goes to the selling shareholders.
What is the minimum investment in the Sahajanand Medical Technologies IPO?
One lot of 43 shares, which costs ₹14,792 at the upper price of ₹344.
When will Sahajanand Medical Technologies list?
The tentative listing date is Fri 23 Oct, with allotment on Wed 21 Oct.
Company figures are from the offer document as summarised by market websites; issue details and subscription are from NSE. Updated 18 Oct 2026, 03:23 PM IST. Education only, not investment advice. Read the offer document, especially the risk factors, before applying. All IPOs →